{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022837","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.676345+00:00","generated_at":"2026-06-22T03:55:04.271997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IDEAYA reports Q3 net income $1.6M; cash $393.9M; darovasertib registrational trial planned Q1 2023","bullets":["Cash equivalents and marketable securities of $393.9M as of Sep 30, 2022, sufficient into 2026.","Q3 net income of $1.6M vs. Q2 net loss of $22.1M; collaboration revenue $29.7M (up from $5.9M).","Targeting initiation of potential registrational trial for darovasertib + crizotinib in MUM in Q1 2023.","Initiated IDE397 Phase 2 monotherapy expansion and combination dose escalation with pemetrexed/taxanes.","Targeting IND for PARG inhibitor IDE161 in Q4 2022 and Pol Theta Helicase FIH study in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022837","json":"https://secwatch.observer/filing/0000950170-22-022837.json","markdown":"https://secwatch.observer/filing/0000950170-22-022837.md","text":"https://secwatch.observer/filing/0000950170-22-022837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/0000950170-22-022837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/idya-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:55:04.271997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23a840809c97b53531d6cdadb27a04bd26e22618","claim":"IDEAYA Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676725/000095017022022837/0000950170-22-022837-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}